VitaDAO

VitaDAO is a pioneering decentralized autonomous organization (DAO) dedicated to funding and advancing early-stage longevity research. As a leader in the decentralized science (DeSci) movement, VitaDAO uses blockchain technology and IP-NFTs to fund research projects and create a community-owned portfolio of longevity assets. Notable for being the first DAO to receive investment from a major pharmaceutical company (Pfizer Ventures).

Location
Decentralized (Global)
Founded
2021
AUM
$10M+ (treasury)
Investment Range
$50K - $500K
Portfolio Companies
7
Focus
dao
Fund Stages
seed

Investment Thesis

VitaDAO funds early-stage longevity research that traditional funding sources often overlook. They focus on projects targeting the fundamental mechanisms of aging with potential for significant healthspan extension. Their decentralized model enables rapid, community-driven funding decisions using IP-NFTs (Intellectual Property Non-Fungible Tokens) for research commercialization.

Team / Governance

Core Contributors & Stewards

  • Tyler Golato - Co-Founder
  • Tim Peterson, PhD - Scientific Lead
  • Laurence Ion - Operations Lead
  • Catthu - Token-holder Representative

Notable Investors

  • Pfizer Ventures - First pharma company to invest in a DAO
  • Shine Capital
  • L1 Digital
  • Balaji Srinivasan - Angel investor
  • Joe Betts-LaCroix - Longevity entrepreneur

Focus Areas

  • Longevity & Aging Biology
  • Senolytics & Senescent Cell Clearance
  • Epigenetic Reprogramming
  • Immune System Rejuvenation
  • Mitochondrial Health
  • Neurodegenerative Disease
  • Metabolic Health

Notable Portfolio Companies & Projects

  • Matrix Biosciences - First biotech spinout (October 2023, $300K)
  • Turn Biotechnologies - mRNA therapeutics for longevity
  • Rubedo.Life - Prodrug discovery platform
  • GERO - AI and physics-based aging research
  • Oisín Biotechnologies - Genetic medicines for sarcopenia ($50K)
  • ApoptoSENS - CAR-NK cells targeting senescent cells ($253K)
  • ImmuneAGE Bio - Immune system rejuvenation
  • BE Therapeutics - Brain tissue replacement
  • Zoe Biosciences - PAI-1 antibody therapeutics

Funding History

  • January 2023 - $4.1 million fundraising round (Pfizer Ventures, Shine Capital, L1 Digital)
  • Deployed - Over $4 million to fund 24+ research projects
  • Treasury - Community-governed VITA token treasury

Unique Model

  • Uses IP-NFTs for research funding and IP commercialization
  • Partnership with MoleculeDAO for IP infrastructure
  • VITA token for governance and community participation
  • Decentralized peer review for project evaluation

Sources

Portfolio Companies

NameLocationFoundedCategories
Matrix BiosciencesRochester, New York, USA2023
therapeuticsbiotech+3
Turn BiotechnologiesMountain View, California, USA2018
therapeuticsbiotech+3
Rubedo Life SciencesSunnyvale, California, USA2019
therapeuticsbiotech+3
ExcepGen Inc--
therapeuticsbiotech+3
GEROSingapore2015
ai-drug-discoverylongevity-research+2
Oisín BiotechnologiesSeattle, Washington, USA2016
biotechlongevity+3
ApoptoSENSUnited States2022
biotechlongevity+3